Richard Stone
MD
Program Director, Adult Leukemia Program
👥Biography 个人简介
Richard Stone at Dana-Farber led the QuANTUM-First trial establishing quizartinib (a selective FLT3 inhibitor) plus chemotherapy as a new first-line standard for FLT3-ITD AML. He has been a central figure in AML clinical research, contributing to multiple landmark trials and to the development and validation of FLT3 inhibitors as a key therapeutic class for this genetically defined AML subtype.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-02-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 Richard Stone 的研究动态
Follow Richard Stone's research updates
留下邮箱，当我们发布与 Richard Stone（Dana-Farber Cancer Institute）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment